Latest JOHNSON & JOHNSON Stock Portfolio
JOHNSON & JOHNSON Performance:
2025 Q4: 12.64%YTD: 51.06%2024: -16.62%
Performance for 2025 Q4 is 12.64%, and YTD is 51.06%, and 2024 is -16.62%.
About JOHNSON & JOHNSON and 13F Hedge Fund Stock Holdings
On 2026-03-18, the fund reported it's updated stock portfolio. In the 13F Holdings report, JOHNSON & JOHNSON reported an equity portfolio of $555 Millions as of 31 Dec, 2025.
The top stock holdings of JOHNSON & JOHNSON are PTGX, NBTX, . The fund has invested 38.5% of it's portfolio in PROTAGONIST THERAPEUTICS INC. and 23.4% of portfolio in NANOBIOTIX S.A.
The fund managers got completely rid off ARROWHEAD PHARMACEUTICALS, INC. (ARWR), VOR BIOPHARMA, INC. (VOR) and ADICET BIO, INC. (ACET) stocks. They significantly reduced their stock positions in CVRX, INC. (CVRX). JOHNSON & JOHNSON opened new stock positions in VOR BIOPHARMA, INC. (VOR) and ADICET BIO, INC. (ACET).
The top stock holdings of JOHNSON & JOHNSON are PTGX, NBTX, . The fund has invested 38.5% of it's portfolio in PROTAGONIST THERAPEUTICS INC. and 23.4% of portfolio in NANOBIOTIX S.A.
The fund managers got completely rid off ARROWHEAD PHARMACEUTICALS, INC. (ARWR), VOR BIOPHARMA, INC. (VOR) and ADICET BIO, INC. (ACET) stocks. They significantly reduced their stock positions in CVRX, INC. (CVRX). JOHNSON & JOHNSON opened new stock positions in VOR BIOPHARMA, INC. (VOR) and ADICET BIO, INC. (ACET).
JOHNSON & JOHNSON Annual Return Estimates Vs S&P 500
Our best estimate is that JOHNSON & JOHNSON made a return of 12.64% in the last quarter. In trailing 12 months, it's portfolio return was 51.06%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| vor biopharma, inc. | 702,815 |
| adicet bio, inc. | 191,803 |
New stocks bought by JOHNSON & JOHNSON
Additions
Reductions
| Ticker | % Reduced |
|---|---|
| cvrx, inc. | -1.91 |
JOHNSON & JOHNSON reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| arrowhead pharmaceuticals, inc. | -8,539,660 |
| vor biopharma, inc. | -2,617,820 |
| adicet bio, inc. | -295,295 |
| biomx inc. | -50,855 |
| senseonics holdings, inc. | -23,804 |
JOHNSON & JOHNSON got rid off the above stocks
Sector Distribution
JOHNSON & JOHNSON has about 58.9% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 58.9 |
| Others | 41.1 |
Market Cap. Distribution
JOHNSON & JOHNSON has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- MID-CAP
- SMALL-CAP
- MICRO-CAP
| Category | % |
|---|---|
| UNALLOCATED | 41.1 |
| MID-CAP | 38.5 |
| SMALL-CAP | 14 |
| MICRO-CAP | 5.9 |
Stocks belong to which Index?
About 58.9% of the stocks held by JOHNSON & JOHNSON either belong to S&P 500 or RUSSELL 2000 index.
- RUSSELL 2000
- Others
| Index | % |
|---|---|
| RUSSELL 2000 | 58.9 |
| Others | 41.1 |
JOHNSON & JOHNSON Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of JOHNSON & JOHNSON
JOHNSON & JOHNSON has 17 stocks in it's portfolio. About 98.3% of the portfolio is in top 10 stocks. LEGN proved to be the most loss making stock for the portfolio. PTGX was the most profitable stock for JOHNSON & JOHNSON last quarter.
Last Reported on: 18 Mar, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACET | adicet bio, inc. | 0.04 | 22,779 | 191,803 | new | |||
| ACET | adicet bio, inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ARWR | arrowhead pharmaceuticals, inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CVRX | cvrx, inc. | 5.15 | 4,024,860 | 28,576,500 | reduced | -1.91 | ||
| FATE | fate therapeutics, inc. | 0.60 | 3,379,060 | 3,320,270 | unchanged | 0.00 | ||
| LAB | standard biotools, inc. | 0.07 | 311,967 | 399,318 | unchanged | 0.00 | ||
| LEGN | legend biotech corporation | 3.19 | 814,586 | 17,709,100 | unchanged | 0.00 | ||
| LYEL | lyell immunopharma, inc. | 0.30 | 54,887 | 1,689,420 | unchanged | 0.00 | ||
| MGTX | meiragtx holdings plc | 9.51 | 6,641,060 | 52,796,500 | unchanged | 0.00 | ||
| NBTX | nanobiotix s.a. | 23.42 | 5,623,820 | 130,023,000 | unchanged | 0.00 | ||
| NNOX | nano-x imaging ltd. | 0.08 | 158,852 | 444,786 | unchanged | 0.00 | ||
| PHGE | biomx inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| PRCT | procept biorobotics corporation | 2.03 | 357,939 | 11,260,800 | unchanged | 0.00 | ||
| PTGX | protagonist therapeutics inc. | 38.54 | 2,449,180 | 213,912,000 | unchanged | 0.00 | ||
| RLYB | rallybio corporation | 0.45 | 454,545 | 2,494,910 | unchanged | 0.00 | ||
| SENS | senseonics holdings, inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| VOR | vor biopharma, inc. | 0.13 | 53,732 | 702,815 | new | |||
| VOR | vor biopharma, inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| XNCR | xencor, inc. | 2.06 | 748,062 | 11,452,800 | unchanged | 0.00 | ||
| rapport therapeutics, inc. | 9.76 | 1,784,520 | 54,142,200 | unchanged | 0.00 | |||